This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.
Unifiram
Surface here is educational only; do not use without medical supervision. Our editorial verdict is SKIP-FOR-NOW — current cost / risk / redundancy puts it below the line.
Our depth — beyond the mirror
Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.
▸ Editor's verdict SKIP-FOR-NOW LOW
"Zero human data of any kind, sourcing reliability variable, and cleaner same-class options exist (aniracetam has decades of clinical use; TAK-653 has modern human safety data; sunifiram has slightly more in-vitro mechanism characterization). The '1000× more potent than piracetam' claim is a rodent passive-avoidance dose ratio that has never been validated in humans. Unifiram offers no clear advantage over sunifiram in the published animal record. Would upgrade to WATCH-LIST only if (a) a human dose-finding study appeared, (b) a vendor with verified COAs emerged, and (c) a published comparison demonstrated unifiram-specific advantage over sunifiram."
▸ Decision matrix by user profile Per-archetype
| Archetype | Verdict | Rationale |
|---|---|---|
★20-30, brain-priority, high cognitive workload (this-archetype) | SKIP-FOR-NOW | No human data; sunifiram is slightly better characterized; TAK-653 and aniracetam dominate the broader niche. |
30-50, executive maintenance | SKIP | Same reasoning. |
50+, mild cognitive decline | SKIP | Aniracetam (clinical use in Europe/Asia for cognitive decline) is the appropriate racetam-family option in this niche. |
Anxiety-prone | SKIP | pro-glutamatergic stimulation reportedly worsens anxiety in a subset of users. |
High athletic load, tested status | SKIP | undefined banned-substance status; WADA-unscheduled but the regulatory landscape for research chemicals can shift. |
Sleep-disordered | SKIP | daytime only at best; seizure-threshold concern compounds with sleep deprivation. |
Recovery-focused | SKIP | no relevant evidence. |
Strength/anabolic-focused | I | — |
- ★20-30, brain-priority, high cognitive workload (this-archetype)SKIP-FOR-NOW
No human data; sunifiram is slightly better characterized; TAK-653 and aniracetam dominate the broader niche.
- 30-50, executive maintenanceSKIP
Same reasoning.
- 50+, mild cognitive declineSKIP
Aniracetam (clinical use in Europe/Asia for cognitive decline) is the appropriate racetam-family option in this niche.
- Anxiety-proneSKIP
pro-glutamatergic stimulation reportedly worsens anxiety in a subset of users.
- High athletic load, tested statusSKIP
undefined banned-substance status; WADA-unscheduled but the regulatory landscape for research chemicals can shift.
- Sleep-disorderedSKIP
daytime only at best; seizure-threshold concern compounds with sleep deprivation.
- Recovery-focusedSKIP
no relevant evidence.
- Strength/anabolic-focusedI
▸ Subjective experience (deep)
Per forum reports (low confidence — small N, no purity standardization):
- Onset 20-60 min sublingual or oral
- Mild verbal fluency boost
- Working-memory smoothing
- Some reports of mild stimulation; others report it does nothing
- Duration 3-6 hours
- Headache and irritability with daily or higher-dose use
- Subjectively similar to sunifiram in most reports — some users prefer one over the other but the basis is unclear
▸ Tolerance + cycling deep dive
- Tolerance buildup: Unknown in humans. Glutamatergic mechanisms generally show tolerance with daily dosing in rodents.
- Recommended cycle: N/A — no validated protocol. Forum convention is intermittent dosing 1-3× per week.
- Reset protocol if needed: Unknown.
▸ Stacking deep dive
Synergistic with
- Cholinergic precursors (alpha-GPC, citicoline): Forum convention by analogy with sunifiram — AMPA potentiation increases acetylcholine demand, so a choline floor reduces headache risk.
- Aniracetam: Theoretically additive AMPA potentiation; risk = compounded seizure-threshold concern.
Avoid stacking with
- Sunifiram, IDRA-21, TAK-653: Additive AMPA modulation = additive seizure liability and redundant mechanism.
- Bupropion, tramadol, high-dose modafinil: Independent seizure-threshold liability.
- Sleep deprivation: Lowers seizure threshold.
Neutral / safe co-administration
Unstudied. Common forum stack: + alpha-GPC + caffeine + theanine.
▸ Drug interactions deep dive
None characterized in humans. CYP profile not published. No drug-drug interaction studies exist.
▸ Pharmacogenomics
Unknown. No human pharmacogenomic data.
▸ Sourcing deep dive
| Path | Vendor | Cost | Reliability | Notes |
|---|---|---|---|---|
| Research chemical | Various RC vendors | $30-80 / gram | Low-medium | Some vendors provide COA, most do not; potency variable; smaller vendor footprint than sunifiram; not for human consumption per vendor disclaimers |
Sourcing reliability is variable — unifiram has a smaller vendor footprint than sunifiram, and several historical vendors of unifiram have been intermittent or have shipped material with no COA. This is a real practical concern: if a user did want to experiment, sunifiram has slightly better sourcing and slightly more pharmacology characterization, making unifiram strictly dominated within the DM-series.
▸ Biomarkers to track (deep)
- N/A — not recommended for use. If used despite recommendation, subjective cognitive performance scales (e.g., self-rated focus/recall) and mood scales (PHQ-9, GAD-7) would be the bare minimum, plus a baseline seizure-history screen.
▸ Controversies / open debates Live debate
- The "1000× more potent than piracetam" claim is a rodent passive-avoidance dose ratio (typical effective unifiram dose ~0.01 mg/kg vs piracetam ~10-30 mg/kg in the same paradigm). It has never been validated in humans, has not been replicated in non-passive-avoidance paradigms with the same magnitude, and conflates a behavioral-readout dose with a clinical effect size. The claim should be treated as folklore in a human context.
- The Italian academic group that produced unifiram and sunifiram never advanced either compound to human trials. Why is unclear — likely a combination of seizure liability concerns, IP/funding constraints, and the broader collapse of cognitive-enhancement drug development in the early 2000s.
- Forum users sometimes rank sunifiram > unifiram in subjective potency; sometimes the reverse. With no purity controls and no objective testing, this ranking is essentially noise.
- The label "racetam-class" is technically incorrect — neither unifiram nor sunifiram contains the pyrrolidone ring. The community uses "racetam" loosely to mean "cognitive enhancer with similar behavioral profile."
▸ Verdict change log
- 2026-05-10 — Initial verdict: SKIP-FOR-NOW (LOW confidence). Zero human data, variable sourcing, dominated by sunifiram in the DM-series and by aniracetam / TAK-653 in the broader niche.
▸ Open questions / gaps Open
- Zero human PK, zero Phase 1 — entire pharmacology in humans is forum-derived.
- Half-life in humans is unknown.
- Whether unifiram has the same NMDA glycine-site activity as sunifiram is plausible but not directly published.
- Whether the unifiram-vs-sunifiram subjective distinction reflects real pharmacological difference or vendor purity variation is unresolved.
- A credible GMP source would change the calculus marginally — but the absence of human safety data would still dominate.
References
Galeotti et al. 2007 — Different involvement of type 1, 2, and 3 ryanodine receptors in memory processes (passive avoidance, sunifiram and unifiram in mice) (Pharmacol Biochem Behav)
Romero et al. 2002 — Sunifiram (DM-235) cognition enhancer characterization (Eur J Pharmacol)
Lynch 2006 — Glutamate-based therapeutic approaches: ampakines and racetams (review)
Martini et al. 2013 — Sunifiram NMDA glycine-site partial agonism (sister-compound mechanism reference)
How was your experience with this compound?
Anonymous · one vote per session · results below at 5+ votes.
See something off?
Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.